Abstract
Anti–PD1–based immune checkpoint blockade (ICB) treatment (Tx) is the standard therapy for R/M HNSCC but the objective response rate is low (<20%). Currently, PD-L1 expression is the only biomarker used in the clinic, however, the predictive value is low. The data on the correlation between ICB outcomes and genomic characteristics is scant. Here, we report a single institutional data of clinical outcomes and genomic characteristics of patients (pts) with R/M HNSCC treated with ICB-based therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have